Evidence map›Paper›PMID 31675684›Full record

ArticleBreast (Edinburgh, Scotland)2020

Comparison of outcomes between metaplastic and triple-negative breast cancer patients.

Praveen Polamraju, Waqar Haque, Kevin Cao, Vivek Verma, Mary Schwartz, V Suzanne Klimberg, Sandra Hatch, Polly Niravath, E Brian Butler, Bin S Teh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Praveen PolamrajuDepartment of Radiation Oncology, University of Texas Medical Branch, Galveston, TX, USA.
Waqar HaqueDepartment of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA. Electronic address: waqarh786@gmail.com.
Kevin CaoDepartment of Radiation Oncology, University of Texas Medical Branch, Galveston, TX, USA.
Vivek VermaDepartment of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, USA.
Mary SchwartzDepartment of Pathology, Houston Methodist Hospital, Houston, TX, USA.
V Suzanne KlimbergDepartment of Surgery, University of Texas Medical Branch, Galveston, TX, USA.
Sandra HatchDepartment of Radiation Oncology, University of Texas Medical Branch, Galveston, TX, USA.
Polly NiravathDepartment of Medical Oncology, Houston Methodist Hospital, Houston, TX, USA.
E Brian ButlerDepartment of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA.
Bin S TehDepartment of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetaplastic breast cancer (MBC) is a rare, aggressive variant of breast cancer that has been associated with poor clinical outcomes, as has triple-negative breast (TNBC) cancer. Limited studies compare the clinical characteristics and prognosis of MBC to TNBC. This study uses a large, contemporary US cancer database to compare clinical characteristics and survival outcomes for patients with MBC to those with TNBC.

methodsThe National Cancer Database was queried for women with cT1-4N1-3M0 MBC or TNBC diagnosed between 2004 and 2013 and treated with definitive surgery. Chi-squared analysis was performed to determine differences between the cohorts. Kaplan-Meier curves compared overall survival (OS), and Cox regression determined patient factors associated with OS.

resultsAltogether, 55,847 patients met the inclusion criteria; 50,705 (90.8%) had TNBC and 5,142 (9.2%) had MBC. Most patients had no comorbid conditions (82%), N0 disease (71%), poorly differentiated histology (77%), received chemotherapy (87%), and received radiation therapy (60%). Amongst all patients, patients with TNBC disease were observed to have greater OS than those with MBC (5-year OS 72.0% vs 55.8%, p < 0.001). The greater observed OS for patients with TNBC persisted when controlling for stage and when comparing propensity score matched cohorts. On Cox regression, lower age, T1 status, N0 status, chemotherapy, TNBC disease, and radiation therapy (RT) were associated with improved OS.

conclusionsMBC had an association with poorer OS compared to TNBC, while RT and chemotherapy receipt were associated with improved OS for patients regardless of stage. Further studies are needed to corroborate the conclusions herein.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Ductal, BreastCase-Control StudiesCombined Modality TherapyDatabases, FactualFemaleHumansLogistic ModelsMiddle AgedMultivariate AnalysisPrognosisRetrospective StudiesSurvival AnalysisTriple Negative Breast NeoplasmsBreast cancerChemotherapyMetaplasticRadiation therapyTriple-negative

Identifiers

PMID31675684
PMCPMC7375639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.